A Sharply Defined Pattern of Central Retinal Thinning
Imagine an archery target where the outer rings stay crisp and vivid while only the innermost bullseye fades away — a strange, localised kind of wear that leaves everything around it untouched. Central areolar choroidal dystrophy behaves in much the same way on a retinal examination: a sharply defined zone of atrophy sitting directly beneath the macula, with the surrounding retina and choroid remaining largely intact. It's this sharply cut boundary, rather than any gradual fade, that tends to catch an examiner's attention first.
Somali patients typically present with this condition in their thirties or forties, often after a routine eye check turned up a pale, unusually precise patch that a local ophthalmologist correctly flagged as atypical for ordinary age-related change at that stage of life.
Most people only realise something has changed once they look back — perhaps small print has quietly grown harder to read over a couple of years, or they've started angling their head slightly to bring a face into sharper focus off to one side. A sharply outlined dark or grey patch takes hold right in the centre of vision as things progress, yet everyday tasks like moving through a busy room or spotting a doorway stay completely unaffected, since the disease keeps strictly to that one small central window and leaves dim-light vision alone entirely.
In the majority of confirmed cases, a fault in the PRPH2 gene is to blame — this gene builds a structural protein that photoreceptor cells rely on to keep their shape and do their job. Once it stops working, three layers packed tightly beneath the macula give way together as a single unit: the choriocapillaris, the retinal pigment epithelium, and the photoreceptors sitting just above them — but the damage stays boxed into that one small region rather than drifting outward. Most families see it passed down as a dominant trait, showing up generation after generation.
The atrophic area tends to catch the eye with an unusually sharp, almost drawn-with-a-ruler edge, and fundus autofluorescence is the tool we lean on to map that boundary as precisely as possible. Alongside it, OCT tells us how much photoreceptor tissue is holding on right at the rim — frequently the detail that matters most for what comes next. A near-normal electroretinogram is genuinely reassuring here, since it tells us the process has stayed contained rather than spreading, and a PRPH2 genetic test wraps up the diagnostic picture.
Instead of following one fixed routine, we pace care around how quickly the atrophic zone is actually expanding, judged through imaging spaced out over repeat visits rather than a single look. Patients who qualify are considered for regenerative stem cell therapy, with the goal of supporting retina that's still functioning at the border of the affected area, and as the central blind spot becomes more defined, we work through practical low-vision strategies that fit the specific shape of what a patient is experiencing.
Not at all — that's actually consistent with the diagnosis rather than a reason to doubt it. This condition stays confined to a small central area and leaves the rod cells that handle night vision untouched, so seeing in the dark usually holds up fine even as reading grows harder.
There isn't really a fixed pattern — some patients barely change over ten years of follow-up, while others see it move faster within just a few. That's exactly why we rely on repeated imaging over time instead of predicting a single growth curve.
They can look alike side by side, but the causes and timing are quite different — yours from an inherited gene fault appearing decades early, hers from age-related change building up much later in life. A genetic test and the age of onset are what tell them apart.
For most people, no — everyday orientation and mobility stay dependable, since the disease sticks to a defined central patch rather than reaching into the wider field of vision that guides how we move through the world.